Vascular invasion in hepatocellular Carcinoma: Prevalence, determinants and prognostic impact

Journal of Clinical Gastroenterology

Volumn 48, Issue 8, 2014, Pages 734-741

  Lee, Yun Hsuan ^a,b   Hsu, Chia Yang ^a,b,c   Huang, Yi Hsiang ^b,d   Hsia, Cheng Yuan ^a,b   Chiou, Yi You ^a,b   Su, Chien Wei ^a,b   Lin, Han Chieh ^a,b   Huo, Teh Ia ^a,b,e  

^a Faculty of Medicine   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Institute of Clinical Medicine   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

hepatocellular carcinoma; mascrovascular invasion; prevalence; prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; BILIRUBIN; CREATININE; HEPATITIS B SURFACE ANTIGEN; SERUM ALBUMIN; SODIUM; UREA;

ABLATION THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOLISM; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CREATININE BLOOD LEVEL; DISTANT METASTASIS; FEMALE; HEPATITIS B; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MACROVASCULAR INVASION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; TUMOR VOLUME; UREA NITROGEN BLOOD LEVEL; AGE; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE; TUMOR INVASION;

AGE FACTORS; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR BURDEN;

EID: 84902578196     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182a8a254     Document Type: Article

References (35)

1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5-S16. (Pubitemid 39423365)
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239-245.
4. Hsu CY, Lee YH, Huang YH, et al. Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact and staging strategy. Hepatol Int. 2013;7:188-198.
5. Lee YH, Hsu CY, Hsia CY, et al. Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Dig Liver Dis. 2012;44:868-874.
6. Sakata J, Shirai Y, Wakai T, et al. Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur J Surg Oncol. 2008;34:900-905.
7. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11:1086-1092. (Pubitemid 41341758)
8. Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117:4475-4483.
9. Lee YH, Hsu CY, Huang YH, et al. a-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma. J Gastrointest Surg. 2013;17:730-738.
10. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080-1086. (Pubitemid 32378206)
11. Choi KK, Kim SH, Choi SB, et al. Portal venous invasion: the single most independent risk factor for immediate postoperative recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:1646-1651.
12. EASL-EORTC. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
14. Kikuchi LO, Paranagua-Vezozzo DC, Chagas AL, et al. Nodules less than 20 mm and vascular invasion are predictors of survival in small hepatocellular carcinoma. J Clin Gastro-enterol. 2009;43:191-195.
15. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis. 1988;8:12-25.
16. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655. (Pubitemid 13149996)
17. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastro-enterology. 2003;124:91-96. (Pubitemid 36055342)
18. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470. (Pubitemid 32119037)
19. Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53: 108-117.
20. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115-S120. (Pubitemid 38240111)
21. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723-731.
22. Hsu CY, Hsia CY, Huang YH, et al. Comparison of surgical resection and transarterial chemoembolization for hepato-cellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol. 2012;19:842-849.
23. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699. (Pubitemid 26079803)
24. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010; 31:461-476.
25. de Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol. 2012;56:S75-S87.
26. Hsu CY, Lee YH, Hsia CY, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the BCLC system. Hepatology. 2013;57:112-119.
27. Chen CH, Chang TT, Cheng KS, et al. Do young hepatocel-lular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int. 2006;26:766-773.
28. Su CW, Lei HJ, Chau GY, et al. The effect of age on the longterm prognosis of patients with hepatocellular carcinoma after resection surgery: a propensity score matching analysis. Arch Surg. 2012;147:137-144.
29. Lee YH, Hsu CY, Hsia CY, et al. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int. 2013;7:645-654.
30. Tandon P, Garcia-Tsao G. Prognostic indicators in hepato-cellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510.
31. Lee YH, Hsu CY, Hsia CY, et al. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Aliment Pharmacol Ther. 2012;36:551-559.
32. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442. (Pubitemid 36152543)
33. Peng ZW, Guo RP, Zhang YJ, et al. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2012;118:4725-4736.
34. Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma. Surg Oncol Clin N Am. 2003;12:25-34.
35. Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008;15:1375-1382.